Ok, I'll bite - what is a "ligand driven cancer" and how is it different than a "mutation driven cancer" - since to my knowledge all cancers are ultimately mutation driven?
THE DRUG, IMO, is JUNK, in ligand-driven cancers (as seen in two recent Phase 2 trials - colon cancer and ovarian cancer).
Are you saying that for colon and ovarian cancer the mutation is elsewhere (in non-hedgehog pathways) and only indirectly (how?) effects the hedgehog pathways? Or are you saying something different?
Market Data 
Markets 
AI
